FI3982960T3 - Perinnöllisen angioödeeman hoitoja - Google Patents
Perinnöllisen angioödeeman hoitoja Download PDFInfo
- Publication number
- FI3982960T3 FI3982960T3 FIEP20734283.3T FI20734283T FI3982960T3 FI 3982960 T3 FI3982960 T3 FI 3982960T3 FI 20734283 T FI20734283 T FI 20734283T FI 3982960 T3 FI3982960 T3 FI 3982960T3
- Authority
- FI
- Finland
- Prior art keywords
- compound
- formula
- solvate
- pharmaceutically acceptable
- acceptable salt
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Dermatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Neurology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Otolaryngology (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962861725P | 2019-06-14 | 2019-06-14 | |
| GBGB1910116.1A GB201910116D0 (en) | 2019-07-15 | 2019-07-15 | Treatments of hereditary angioedema |
| PCT/GB2020/051439 WO2020249977A1 (en) | 2019-06-14 | 2020-06-15 | Treatments of hereditary angioedema |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| FI3982960T3 true FI3982960T3 (fi) | 2023-08-29 |
Family
ID=67700145
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FIEP20734283.3T FI3982960T3 (fi) | 2019-06-14 | 2020-06-15 | Perinnöllisen angioödeeman hoitoja |
Country Status (34)
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201609607D0 (en) | 2016-06-01 | 2016-07-13 | Kalvista Pharmaceuticals Ltd | Polymorphs of N-(3-Fluoro-4-methoxypyridin-2-yl)methyl)-3-(methoxymethyl)-1-({4-((2-oxopy ridin-1-yl)methyl)phenyl}methyl)pyrazole-4-carboxamide and salts |
| GB201719881D0 (en) | 2017-11-29 | 2018-01-10 | Kalvista Pharmaceuticals Ltd | Solid forms of plasma kallikrein inhibitor and salts thereof |
| GB201910116D0 (en) * | 2019-07-15 | 2019-08-28 | Kalvista Pharmaceuticals Ltd | Treatments of hereditary angioedema |
| WO2021028645A1 (en) | 2019-08-09 | 2021-02-18 | Kalvista Pharmaceuticals Limited | Plasma kallikrein inhibitors |
| WO2022084693A1 (en) * | 2020-10-23 | 2022-04-28 | Kalvista Pharmaceuticals Limited | Treatments of angioedema |
| JP2024505596A (ja) * | 2021-02-09 | 2024-02-06 | カルビスタ・ファーマシューティカルズ・リミテッド | 遺伝性血管性浮腫の治療 |
| US20250281397A1 (en) | 2022-04-27 | 2025-09-11 | Kalvista Pharmaceuticals Limited | Formulations of a plasma kallikrein inhibitor |
| CN116003386B (zh) * | 2022-11-20 | 2024-03-26 | 药康众拓(北京)医药科技有限公司 | 一种氘代n-苄基吡啶酮吡唑甲酰胺类化合物、药物组合物和用途 |
| WO2025172693A1 (en) | 2024-02-13 | 2025-08-21 | Kalvista Pharmaceuticals Limited | Oral sebetralstat for the treatment of an attack of hereditary angioedema |
| WO2025172692A1 (en) | 2024-02-13 | 2025-08-21 | Kalvista Pharmaceuticals Limited | Oral sebetralstat for the treatment of an attack of hereditary angioedema |
| WO2026003532A1 (en) | 2024-06-28 | 2026-01-02 | Kalvista Pharmaceuticals Limited | Sebetralstat for the treatment of anxiety associated with hereditary angioedema |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5187157A (en) | 1987-06-05 | 1993-02-16 | Du Pont Merck Pharmaceutical Company | Peptide boronic acid inhibitors of trypsin-like proteases |
| GB9019558D0 (en) | 1990-09-07 | 1990-10-24 | Szelke Michael | Enzyme inhibitors |
| SE9301911D0 (sv) | 1993-06-03 | 1993-06-03 | Ab Astra | New peptide derivatives |
| US5589467A (en) | 1993-09-17 | 1996-12-31 | Novo Nordisk A/S | 2,5',N6-trisubstituted adenosine derivatives |
| GB0205527D0 (en) | 2002-03-08 | 2002-04-24 | Ferring Bv | Inhibitors |
| US7429604B2 (en) | 2004-06-15 | 2008-09-30 | Bristol Myers Squibb Company | Six-membered heterocycles useful as serine protease inhibitors |
| EP2051707B1 (en) | 2006-07-31 | 2013-07-17 | Activesite Pharmaceuticals, Inc. | Inhibitors of plasma kallikrein |
| DE102006050672A1 (de) | 2006-10-24 | 2008-04-30 | Curacyte Discovery Gmbh | Hemmstoffe des Plasmins und des Plasmakallikreins |
| JP2013121919A (ja) | 2010-03-25 | 2013-06-20 | Astellas Pharma Inc | 血漿カリクレイン阻害剤 |
| ES2483802T3 (es) | 2010-07-07 | 2014-08-07 | The Medicines Company (Leipzig) Gmbh | Inhibidores de serina proteasa |
| EP2595986A2 (en) | 2010-07-14 | 2013-05-29 | Addex Pharma SA | Novel 2-amino-4-pyrazolyl-thiazole derivatives and their use as allosteric modulators of metabotropic glutamate receptors |
| US9290485B2 (en) | 2010-08-04 | 2016-03-22 | Novartis Ag | N-((6-amino-pyridin-3-yl)methyl)-heteroaryl-carboxamides |
| GB2494851A (en) | 2011-07-07 | 2013-03-27 | Kalvista Pharmaceuticals Ltd | Plasma kallikrein inhibitors |
| GB201300304D0 (en) | 2013-01-08 | 2013-02-20 | Kalvista Pharmaceuticals Ltd | Benzylamine derivatives |
| RU2712621C2 (ru) | 2013-05-23 | 2020-01-30 | Калвиста Фармасьютикалз Лимитед | Азотсодержащие гетероциклические производные, полезные в качестве ингибитора калликреина плазмы |
| EP2815749A1 (en) * | 2013-06-20 | 2014-12-24 | IP Gesellschaft für Management mbH | Solid form of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione having specified X-ray diffraction pattern |
| EP2886107A1 (en) * | 2013-12-17 | 2015-06-24 | ObsEva S.A. | Oral formulations of pyrrolydine derivatives |
| GB201421083D0 (en) | 2014-11-27 | 2015-01-14 | Kalvista Pharmaceuticals Ltd | Enzyme inhibitors |
| GB201609607D0 (en) * | 2016-06-01 | 2016-07-13 | Kalvista Pharmaceuticals Ltd | Polymorphs of N-(3-Fluoro-4-methoxypyridin-2-yl)methyl)-3-(methoxymethyl)-1-({4-((2-oxopy ridin-1-yl)methyl)phenyl}methyl)pyrazole-4-carboxamide and salts |
| GB201721515D0 (en) * | 2017-12-21 | 2018-02-07 | Kalvista Pharmaceuticals Ltd | Dosage forms comprising a plasma kallikrein inhibtor |
| GB201910116D0 (en) * | 2019-07-15 | 2019-08-28 | Kalvista Pharmaceuticals Ltd | Treatments of hereditary angioedema |
-
2019
- 2019-07-15 GB GBGB1910116.1A patent/GB201910116D0/en not_active Ceased
-
2020
- 2020-06-15 US US17/617,439 patent/US20220218680A1/en active Pending
- 2020-06-15 EA EA202193019A patent/EA202193019A1/ru unknown
- 2020-06-15 WO PCT/GB2020/051439 patent/WO2020249977A1/en not_active Ceased
- 2020-06-15 LT LTEPPCT/GB2020/051439T patent/LT3982960T/lt unknown
- 2020-06-15 HU HUE20734283A patent/HUE063163T2/hu unknown
- 2020-06-15 MA MA56187A patent/MA56187B1/fr unknown
- 2020-06-15 BR BR112021024664A patent/BR112021024664A2/pt not_active Application Discontinuation
- 2020-06-15 MY MYPI2021007320A patent/MY205687A/en unknown
- 2020-06-15 EP EP20734283.3A patent/EP3982960B1/en active Active
- 2020-06-15 ES ES20734283T patent/ES2956471T3/es active Active
- 2020-06-15 MD MDE20220440T patent/MD3982960T2/ro unknown
- 2020-06-15 AU AU2020293614A patent/AU2020293614B2/en active Active
- 2020-06-15 CN CN202080043365.6A patent/CN114126612A/zh active Pending
- 2020-06-15 JP JP2021571931A patent/JP7356518B2/ja active Active
- 2020-06-15 PH PH1/2021/552966A patent/PH12021552966A1/en unknown
- 2020-06-15 DK DK20734283.3T patent/DK3982960T3/da active
- 2020-06-15 UA UAA202106869A patent/UA129869C2/uk unknown
- 2020-06-15 TW TW109120108A patent/TW202112370A/zh unknown
- 2020-06-15 PT PT207342833T patent/PT3982960T/pt unknown
- 2020-06-15 SI SI202030247T patent/SI3982960T1/sl unknown
- 2020-06-15 MX MX2021014557A patent/MX2021014557A/es unknown
- 2020-06-15 FI FIEP20734283.3T patent/FI3982960T3/fi active
- 2020-06-15 EP EP23181261.1A patent/EP4282474A3/en active Pending
- 2020-06-15 RS RS20230620A patent/RS64412B1/sr unknown
- 2020-06-15 SG SG11202113304YA patent/SG11202113304YA/en unknown
- 2020-06-15 SM SM20230261T patent/SMT202300261T1/it unknown
- 2020-06-15 KR KR1020217043374A patent/KR102748728B1/ko active Active
- 2020-06-15 PL PL20734283.3T patent/PL3982960T3/pl unknown
- 2020-06-15 HR HRP20230696TT patent/HRP20230696T1/hr unknown
- 2020-06-15 CA CA3142218A patent/CA3142218A1/en active Pending
- 2020-06-16 AR ARP200101681A patent/AR119158A1/es unknown
-
2021
- 2021-12-02 IL IL288615A patent/IL288615A/en unknown
- 2021-12-06 CL CL2021003244A patent/CL2021003244A1/es unknown
- 2021-12-20 ZA ZA2021/10685A patent/ZA202110685B/en unknown
-
2023
- 2023-03-06 CL CL2023000639A patent/CL2023000639A1/es unknown
- 2023-08-14 JP JP2023131860A patent/JP7688078B2/ja active Active
-
2025
- 2025-05-21 JP JP2025084646A patent/JP2025124716A/ja active Pending
-
2026
- 2026-03-09 US US19/561,239 patent/US20260199312A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022536287A5 (cg-RX-API-DMAC7.html) | ||
| HRP20230696T1 (hr) | Liječenje hereditarnog angioedema | |
| JP2022537913A5 (cg-RX-API-DMAC7.html) | ||
| RU2004129324A (ru) | Применения бисфосфоновых кислот для лечения и профилактики остеопороза | |
| JP2011168580A (ja) | 医薬組成物 | |
| JPH0920659A (ja) | 炎症性腹部疾患のためのカッパ−アヘン製剤作働薬 | |
| CN1744897A (zh) | 结合有泰妥拉唑与消炎剂的药物组合物 | |
| CN102036669A (zh) | 用于治疗早泄的药物组合物 | |
| US3557292A (en) | Compositions and methods for treating parkinson's disease with combinations of l-3,4-dihydroxyphenylalanine and a hydrazine | |
| Shao et al. | Treatment of infantile hemangioma by intralesional injection of propranolol combined with compound betamethasone | |
| US20120277318A1 (en) | Non-steroidal anti-inflammatory drugs for cough | |
| IE851848L (en) | Propiophenone compound against sexual dysfunction | |
| JP2023516753A5 (cg-RX-API-DMAC7.html) | ||
| US20150079183A1 (en) | Lercanidipine Hydrochloride and Losartan Potassium Compound Preparation and Preparation Method Thereof | |
| KR100692235B1 (ko) | 안지오텐신 ⅱ 길항물질의 신규한 용도 | |
| US20190224208A1 (en) | Pharmaceutical composition for treating premature ejaculation and method for treating premature ejaculation | |
| NZ782935B2 (en) | Treatments of hereditary angioedema | |
| JP2024520138A (ja) | １－（３－シアノ－１－イソプロピル－インドール－５－イル）ピラゾール－４－カルボン酸を含む薬学的組成物 | |
| US5876751A (en) | Antispasmodic and antinflammatory composition and a process for the manufacture thereof | |
| CN100409850C (zh) | 2h-[1,3]-噁嗪并[3,2-a]吲哚衍生物在制备治疗神经性疼痛的药物中的用途 | |
| NO333599B1 (no) | Anvendelse av distrontiumsalter av 2-[N,N-di(karboksymetyl)amino]-3-cyano-4-karboksymetyl-tiofen-5-karboksylsyre for fremstillingen av medikamenter for behandlingen av gastro-duodenal smerte | |
| FI4021575T3 (fi) | Menetelmiä cln2-taudin hoitamiseksi lapsikohteissa | |
| CN112999214A (zh) | 高香草酸在制备抗血小板、抗血栓形成药物中的应用 | |
| CN114080221B (zh) | 用于减轻疼痛的布洛芬与曲马多的组合 | |
| CN101014333A (zh) | 包含洛索洛芬的口服组合物 |